MicroRNA-18a induces epithelial-mesenchymal transition like cancer stem cell phenotype via regulating RKIP pathway in pancreatic cancer

Honggang Kang, Dan Ma, Jing Zhang, Jun Zhao, Mengxiang Yang

Department of Oncology, Liaocheng People's Hospital, Liaocheng 252000, China

Contributions: (I) Conception and design: H Kang, J Zhang; (II) Administrative support: D Ma, J Zhao; (III) Provision of study materials or patients: M Yang; (IV) Collection and assembly of data: H Kang; (V) Data analysis and interpretation: D Ma; (VI) Manuscript writing: All authors; (VII) Final approval of manuscript: All authors.

Correspondence to: Jing Zhang. Department of Oncology, Liaocheng People's Hospital, 67 Dongchang West Road, Liaocheng 252000, China. Email: 40082684@qq.com.

Background: Pancreatic cancer is a devastating invasive disease. Understanding the molecular mechanism of metastasis of this cancer is basis for its treatment and prevention.

Methods: Pancreatic cancer tissues and normal adjacent tissues were collected from patients tour hospital. Western blotting and a sphere growth and invasion assay were performed to conduct analysis. Pancreatic ductal adenocarcinoma cell Line PANC-1 were cultured. To test the level of Raf-1 kinase inhibitor protein (RKIP), immunofluorescence analyses were performed.

Results: In this study, we showed that expression of RKIP was downregulated in pancreatic cancer. RKIP can inhibit epithelial to mesenchymal transition (EMT) in PANC-1 cells. MicroRNA-181a (miR-181a) has a high expression in pancreatic cancer and can induce EMT phenotype by directly degrading RKIP in pancreatic cancer PANC-1 cells.

Conclusions: We concluded that miR-181a induces EMT phenotype through its regulation of RKIP in pancreatic cancer. MicroRNA-18a may be a novel target in the treatment of pancreatic cancer in future.

Keywords: Pancreatic cancer; epithelial to mesenchymal transition (EMT); Raf-1 kinase inhibitor protein (RKIP); cancer stem cells (CSCs); microRNA-181a(miR-181a)

Submitted Nov 19, 2019. Accepted for publication Feb 27, 2020.
doi: 10.21037/atm.2020.03.195

View this article at: http://dx.doi.org/10.21037/atm.2020.03.195

Introduction

Pancreatic cancer is a devastating invasive disease and is the fourth most common cause of deaths attributed to cancer in the USA (1). The high mortality of pancreatic cancer could, at least partly, be associated with metastasis. Epithelial to mesenchymal transition (EMT) plays a key role in metastasis of pancreatic cancer (2). Thus, understanding the molecular mechanism of EMT in pancreatic cancer is important in terms of improving pancreatic cancer prognosis. Previous research has found that Raf-1 kinase inhibitor protein (RKIP) is a suppressor of metastasis in human cancers (3). It is proposed that RKIP is a metastasis suppressor and a promising marker for predicting prognosis of pancreatic cancer. However, the function of RKIP in pancreatic cancer is still unclear (4).

It is well-known that MicroRNAs (miRNAs/miR), as small non-coding RNAs with 19–25 nucleotides, play an essential role as post-transcriptional regulators to gene expression (5). Multiple genes regulated by miRNAs play crucial roles in migration, EMT, invasion, and tumor metastasis (6).

This study aimed to explore the activity of RKIP in pancreatic cancer, so as to understand the molecular mechanism of metastasis of pancreatic cancer.
Methods

Sample collection of pancreatic cancer tissues

Cancer tissues from subjects with pancreatic cancer and adjacent normal tissues were collected from the hospital. All tissues were confirmed by pathologists.

Cell line PANC-1

Pancreatic ductal adenocarcinoma cell line PANC-1 was obtained from the Chinese Academy of Sciences (Shanghai, China) and cultured with Dulbecco's Modified Eagle Medium (DMEM) containing 10% fetal bovine serum (Invitrogen, San Diego, CA, USA) at 37°C with 5% CO₂.

Transfection experiments

RKIP expressing vectors were purchased from Invitrogen, San Diego, CA, USA. Negative control miRNA (anti-miR) and pre-microRNA-181a (pre-miR-181a) were purchased from Ambion. The transfection process was conducted according to the manufacturers’ instructions. The incubation period lasted for 6 hours, before the medium was removed, and the cells were cultured with another medium for a further 48 hours.

Western blot analysis

Incubation with primary antibodies anti-RKIP, anti-N-Cadherin, anti-E-Cadherin, anti-SNAIL1, anti-Vimentin, anti-TGFβ1, anti-Fibronectin, anti-CD44, anti-β-tubulin, and anti-β-actin took place overnight at 4°C. All primary antibodies were purchased from company (1:500; Abcam, Cambridge, MA, USA). IRDye TM-800 conjugated anti-rabbit secondary antibodies (Li-COR, Biosciences, Lincoln, NE, USA) were applied at room temperature for 2 hours. Odyssey™ Infrared Imaging System (Gene Company, Lincoln, NE, USA) was used to determine the specific protein.

Sphere growth and invasion assay

Cells (2.5x10⁷/mL) were seeded for seven days on 0.5% agar precoated 6-well plates in serum-free RPMI1640/1 mM Na-pyruvate. Invasion assay was based on the protocol of the previous study (7).

Quantitative polymerase chain reaction (qPCR) for microRNAs and RKIP

qPCR was performed as previously described (8). Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) served as a housekeeping gene for controlling RNA loading. The PCR primer sequences were: GAPDH: Forward-5’-CGGAGTCACGG ATTTGCTCGTAT-3’, Reverse-5’-AGCCTT CTCCATGGTGGAAGAC-3’. RKIP: Forward-5’-TATGCCGGTGAGCACGACG-3’, Reverse-5’-CCTACTTTCCCAGAGACG-3’. Power SYBR Green PCR Master Mix (TAKARA Cat No. RR820W) was used in this study.

Immunofluorescence analyses

Immunofluorescence analyses were performed according to the manufacturer's instructions. Briefly, anti-RKIP antibody was applied to stain transfected cells. The secondary antibodies were Alexa Fluor 488 goat anti-rabbit IgG antibody and Coverslips (Invitrogen). Use of a confocal laser-scanning microscope (Leica Microsystems, Bensheim, Germany) allowed us to make microscopic observations. The intensity of fluorescence was assessed in a small number of viewing areas with 300 cells for each coverslip, and ImageJ 1.37v software (http://rsb.info.nih.gov/ij/index.html) was used to conduct analysis.

Statistical analysis

Data analysis was conducted using SPSS20.0 software (SPSS Inc., II, Chicago, IL, USA), and the mean level of index between the two groups was determined by Student's t-test. A P value <0.05 was deemed to be statistically significant.

Results

Pancreatic cancer sees lower RKIP expression

To assess the difference between the expression of RKIP mRNA in pancreatic cancer tissues in comparison with its expression in normal adjacent tissues, qPCR was carried out for both sets of tissues. mRNA was separated from 56 pairs of cancerous tissues and adjacent normal tissues. Our results indicated that RKIP mRNA expression in the cancerous tissues were decreased in comparison with the adjacent normal tissues (Figure 1A). Western blotting
was applied to identify protein isolated from the 6 pairs of cancer and adjacent normal tissues, and the results showed that the cancer tissues had lower RKIP expression (Figure 1B).

**RKIP inhibits EMT in pancreatic cancer PANC-1 cells**

To establish how RKIP operates in relation to pancreatic cancer, PANC-1 cells with RKIP-expressing plasmids were transfected. The results revealed that PANC-1 cells transfected with RKIP-expressing plasmids showed slight changes in morphology in PANC-1 cells (Figure 2A) and higher expression of RKIP protein (Figure 2B).

To further verify that MET induced the changes of cell morphology. Expression levels of epithelial and mesenchymal markers were determined between PANC-1 cells that had been transfected with RKIP-expressing plasmids and the empty-vector cells. We found the E-Cadherin (epithelial marker) to be higher and N-Cadherin, Vimentin, SNAIL, TGFB1, and Fibronectin (mesenchymal markers) to be lower in PANC-1 cells that had received RKIP-expressing plasmids (Figure 2B). Our study also identified an RKIP-induced decrease in sphere formation in PANC-1 cells (Figure 2C). We also found that RKIP overexpression could suppress migration and invasion (Figure 2D) in the cells.

**miR-181a can degrade RKIP in PANC-1 cells**

Our results established that an increase in miR-181a was found in cells treated by pre-miR-181a (Figure 3A,B), as well as showing RKIP protein in the pre-miR-181a-transfected cells to be evidently suppressed (Figure 3C).

Furthermore, immunofluorescence analysis was carried out in PANC-1 cells transfected with pre-miR-181a and control miR. In correspondence with the findings of the western blot, the results of immunofluorescence found RKIP protein to be demonstrably suppressed in the cells that had received pre-miR-181a (Figure 3D).

RT-PCR and real-time PCR were then carried out to measure the expression of RKIP mRNA in PANC-1 cells transfected with pre-miR-181a or control miR. The RT-PCR results identified significant downregulation of RKIP mRNA (Figure 3E) in the cells transfected with pre-miR-181a. Real-time PCR also came up with the same results (Figure 3F).

**miR-181a can promote EMT**

This study showed that expression of miR-181a was higher in cancerous tissues than in adjacent normal tissues (Figure 4A). Overexpression of miR-181a caused significant changes in PANC-1 cells morphology (EMT) (Figure 4B). The E-Cadherin (epithelial marker) was inhibited and N-Cadherin and SNAIL1 (mesenchymal markers) were induced by miR-181a in PANC-1 cells (Figure 4C). We also noted that miR-181a in PANC-1 cells increased sphere formation (Figure 4D). In addition, we found that miR-181a could suppress pancreatic cancer stem cell (CSC) markers (CD44 and Tspan8) in PCNA-1 cells (Figure 4E). To detect whether miR-181a could regulate migration and invasion, we performed invasion and migration assay. We found that miR-181a could indeed promote migration and invasion (Figure 4F) in the cells.
Discussion

Raf-1 can lead to the development of tumor-related processes. Deregulated or constitutively active Raf-1 protein, for example, can contribute to changes in cells (9). Amplification and mutation of upstream regulators of Raf-1, including receptor tyrosine kinases (10) and Ras (11), often results in signaling deregulation in tumors via the Raf/MEK/ERK cascade. The activation of Raf-1 has been identified in cells which express oncogenic B-Raf proteins (12). More recently, it has been proposed that RKIP is a metastasis suppressor and could be a promising marker for predicting a better prognosis in pancreatic cancer (4). In line with earlier reports, we found that in pancreatic cancer there is a downregulation in RKIP expression. RKIP can inhibit EMT in line with CSC phenotype in PANC-1 cells. MEK/ERK signaling is a vital part of a wide-ranging group of cellular functions including cell proliferation, differentiation and survival, and it can have a negative impact on the regulation of mouse embryonic stem cell (mESC) self-renewal by antagonizing STAT3 activity (13). We reason that RKIP might inhibit EMT by regulating MEK/ERK. Chemotherapy is a key therapy in the strategic treatment of pancreatic, but it does not succeed at killing all tumor cells, at least in part due to drug resistance of an intrinsic or acquired nature. Emerging evidence indicates that CSCs and EMT-type cells play an important and complicated role in anticancer drug resistance. Thus, we believe that RKIP had a significant effect on drug resistance in the treatment of pancreatic cancer.

EMT cells can have features similar to CSCs, and CSCs exhibit mesenchymal phenotype under most circumstances. A correlation between aberrant miRNA expression, and the presence of CSCs and the acquisition of an EMT phenotype (14) has been identified. We found that miR-
Figure 3 miR-181a can degrade RKIP in pancreatic cancer PANC-1 cells. RKIP, Raf-1 kinase inhibitor protein.

Figure 4 miR-181a is upregulated in pancreatic cancer and it can promote EMT consistent with cancer stem cell phenotype in pancreatic cancer PANC-1 cells. EMT, epithelial-mesenchymal transition. Scale bars, 50 μm.
18a can promote EMT consistent with CSC phenotype by directly degrading RKIP in pancreatic cancer PANC-1 cells.

PTEN is crucial for maintaining stem cells and a decrease can result in CSCs clones emerging and proliferating (15). The expression of PTEN can be suppressed by miR-181a in pancreatic cancer (16). Thus, we reasoned that miR-181a promotes CSC-like features, at least partly, by regulating RKIP and PTEN in pancreatic cancer. Moreover, miR-181a can promote migration by inhibiting MAP2K4 in pancreatic cancer. All the results indicate that miR-181 operates like an oncogene by controlling different tumor suppressive genes in pancreatic cancer.

In conclusion, we established that miR-181a induces EMT phenotype by regulating RKIP in pancreatic cancer. MicroRNA-18a may be a novel target for treatment of pancreatic cancer in future.

Acknowledgments

None.

Footnote

Conflicts of Interest: All authors have completed the ICMJE uniform disclosure form. The authors have no conflicts of interest to declare.

Ethical Statement: The authors are accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.

References


Cite this article as: Kang H, Ma D, Zhang J, Zhao J, Yang M. MicroRNA-18a induces epithelial-mesenchymal transition like cancer stem cell phenotype via regulating RKIP pathway in pancreatic cancer. Ann Transl Med 2019. doi: 10.21037/atm.2020.03.195